Selective use of preoperative chemoradiotherapy for T3 rectal cancer can be justified

Analysis of local recurrence

Se-Jin Baek, Seon Hahn Kim, Jung-Myun Kwak, Jae Sung Cho, Jae Won Shin, Azali Hafiz Yafee Amar, Jin Kim

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Preoperative chemoradiotherapy (CXRT) is performed to reduce local recurrence and improve the rate of radical resection for rectal cancer. Currently, it is recommended for all suspected T3 rectal cancers. However, the survival benefit of this procedure is controversial, and complications of RT are often overlooked. The present study was designed to assess the validity of our institutional policies regarding selective use of preoperative CXRT for T3 rectal cancer. Methods: From September 2006 to May 2010, we retrospectively analyzed data for patients with pathologic T3 rectal cancer, especially those with follow-up for more than 18 months. Patients who underwent RT pre-/postoperatively were excluded. Patients who fulfilled these criteria but did not undergo RT or had incurable distant metastasis were also excluded. Results: Of the 319 patients who underwent surgery for rectal cancer, 183 were diagnosed with T3 cancer. After excluding 58 patients, the final sample included 125 subjects with a mean follow-up of 26.0 months. In all, 94 patients had a follow-up of more than 18 months. Four patients had local recurrences, and the cumulative local recurrence rate was 3.4 % at 18 months and 5.6 % after 2 years. All four had low rectal cancer (mean distance 4.5 ± 1.9 cm). Three were diagnosed as N0 and one as N1. The mean disease-free period was 15.0 months. The distance between the tumor and the anal verge was the only significant risk factor for local recurrence. Conclusions: In this study, the oncologic outcome for T3 rectal cancer without preoperative CXRT was acceptable in terms of local recurrence. Selective use of preoperative CXRT for T3 rectal cancer needs to be further evaluated prospectively.

Original languageEnglish
Pages (from-to)220-226
Number of pages7
JournalWorld Journal of Surgery
Volume37
Issue number1
DOIs
Publication statusPublished - 2013 Jan 1

Fingerprint

Chemoradiotherapy
Rectal Neoplasms
Recurrence
Organizational Policy
Neoplasms
Outcome Assessment (Health Care)
Neoplasm Metastasis
Survival

ASJC Scopus subject areas

  • Surgery

Cite this

Selective use of preoperative chemoradiotherapy for T3 rectal cancer can be justified : Analysis of local recurrence. / Baek, Se-Jin; Kim, Seon Hahn; Kwak, Jung-Myun; Cho, Jae Sung; Shin, Jae Won; Amar, Azali Hafiz Yafee; Kim, Jin.

In: World Journal of Surgery, Vol. 37, No. 1, 01.01.2013, p. 220-226.

Research output: Contribution to journalArticle

@article{73564a5c9db0457b895d946edc5e5aa3,
title = "Selective use of preoperative chemoradiotherapy for T3 rectal cancer can be justified: Analysis of local recurrence",
abstract = "Background: Preoperative chemoradiotherapy (CXRT) is performed to reduce local recurrence and improve the rate of radical resection for rectal cancer. Currently, it is recommended for all suspected T3 rectal cancers. However, the survival benefit of this procedure is controversial, and complications of RT are often overlooked. The present study was designed to assess the validity of our institutional policies regarding selective use of preoperative CXRT for T3 rectal cancer. Methods: From September 2006 to May 2010, we retrospectively analyzed data for patients with pathologic T3 rectal cancer, especially those with follow-up for more than 18 months. Patients who underwent RT pre-/postoperatively were excluded. Patients who fulfilled these criteria but did not undergo RT or had incurable distant metastasis were also excluded. Results: Of the 319 patients who underwent surgery for rectal cancer, 183 were diagnosed with T3 cancer. After excluding 58 patients, the final sample included 125 subjects with a mean follow-up of 26.0 months. In all, 94 patients had a follow-up of more than 18 months. Four patients had local recurrences, and the cumulative local recurrence rate was 3.4 {\%} at 18 months and 5.6 {\%} after 2 years. All four had low rectal cancer (mean distance 4.5 ± 1.9 cm). Three were diagnosed as N0 and one as N1. The mean disease-free period was 15.0 months. The distance between the tumor and the anal verge was the only significant risk factor for local recurrence. Conclusions: In this study, the oncologic outcome for T3 rectal cancer without preoperative CXRT was acceptable in terms of local recurrence. Selective use of preoperative CXRT for T3 rectal cancer needs to be further evaluated prospectively.",
author = "Se-Jin Baek and Kim, {Seon Hahn} and Jung-Myun Kwak and Cho, {Jae Sung} and Shin, {Jae Won} and Amar, {Azali Hafiz Yafee} and Jin Kim",
year = "2013",
month = "1",
day = "1",
doi = "10.1007/s00268-012-1792-9",
language = "English",
volume = "37",
pages = "220--226",
journal = "World Journal of Surgery",
issn = "0364-2313",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Selective use of preoperative chemoradiotherapy for T3 rectal cancer can be justified

T2 - Analysis of local recurrence

AU - Baek, Se-Jin

AU - Kim, Seon Hahn

AU - Kwak, Jung-Myun

AU - Cho, Jae Sung

AU - Shin, Jae Won

AU - Amar, Azali Hafiz Yafee

AU - Kim, Jin

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Background: Preoperative chemoradiotherapy (CXRT) is performed to reduce local recurrence and improve the rate of radical resection for rectal cancer. Currently, it is recommended for all suspected T3 rectal cancers. However, the survival benefit of this procedure is controversial, and complications of RT are often overlooked. The present study was designed to assess the validity of our institutional policies regarding selective use of preoperative CXRT for T3 rectal cancer. Methods: From September 2006 to May 2010, we retrospectively analyzed data for patients with pathologic T3 rectal cancer, especially those with follow-up for more than 18 months. Patients who underwent RT pre-/postoperatively were excluded. Patients who fulfilled these criteria but did not undergo RT or had incurable distant metastasis were also excluded. Results: Of the 319 patients who underwent surgery for rectal cancer, 183 were diagnosed with T3 cancer. After excluding 58 patients, the final sample included 125 subjects with a mean follow-up of 26.0 months. In all, 94 patients had a follow-up of more than 18 months. Four patients had local recurrences, and the cumulative local recurrence rate was 3.4 % at 18 months and 5.6 % after 2 years. All four had low rectal cancer (mean distance 4.5 ± 1.9 cm). Three were diagnosed as N0 and one as N1. The mean disease-free period was 15.0 months. The distance between the tumor and the anal verge was the only significant risk factor for local recurrence. Conclusions: In this study, the oncologic outcome for T3 rectal cancer without preoperative CXRT was acceptable in terms of local recurrence. Selective use of preoperative CXRT for T3 rectal cancer needs to be further evaluated prospectively.

AB - Background: Preoperative chemoradiotherapy (CXRT) is performed to reduce local recurrence and improve the rate of radical resection for rectal cancer. Currently, it is recommended for all suspected T3 rectal cancers. However, the survival benefit of this procedure is controversial, and complications of RT are often overlooked. The present study was designed to assess the validity of our institutional policies regarding selective use of preoperative CXRT for T3 rectal cancer. Methods: From September 2006 to May 2010, we retrospectively analyzed data for patients with pathologic T3 rectal cancer, especially those with follow-up for more than 18 months. Patients who underwent RT pre-/postoperatively were excluded. Patients who fulfilled these criteria but did not undergo RT or had incurable distant metastasis were also excluded. Results: Of the 319 patients who underwent surgery for rectal cancer, 183 were diagnosed with T3 cancer. After excluding 58 patients, the final sample included 125 subjects with a mean follow-up of 26.0 months. In all, 94 patients had a follow-up of more than 18 months. Four patients had local recurrences, and the cumulative local recurrence rate was 3.4 % at 18 months and 5.6 % after 2 years. All four had low rectal cancer (mean distance 4.5 ± 1.9 cm). Three were diagnosed as N0 and one as N1. The mean disease-free period was 15.0 months. The distance between the tumor and the anal verge was the only significant risk factor for local recurrence. Conclusions: In this study, the oncologic outcome for T3 rectal cancer without preoperative CXRT was acceptable in terms of local recurrence. Selective use of preoperative CXRT for T3 rectal cancer needs to be further evaluated prospectively.

UR - http://www.scopus.com/inward/record.url?scp=84871735443&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871735443&partnerID=8YFLogxK

U2 - 10.1007/s00268-012-1792-9

DO - 10.1007/s00268-012-1792-9

M3 - Article

VL - 37

SP - 220

EP - 226

JO - World Journal of Surgery

JF - World Journal of Surgery

SN - 0364-2313

IS - 1

ER -